With all eyes on the explosive neoantigen field watching to see how it can revolutionize cancer immunotherapies and rival the current T cell therapies, it is clear that critical questions still remain to be addressed to ensure full therapeutic success.
Taking place from the comfort of your own home this year, the 5th Neoantigen Based Therapies Summit remains the only industry focused meeting dedicated to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.
View the full event guide for more details on this content packed 3-day virtual event.
We’ll be addressing the most pressing challenges in the field, including:
- Identifying both personalized and shared Neoantigens to supercharge development of next generation immunotherapy with University of Miami and Netherlands Cancer Institute
- Improving prediction accuracy by exploring different neoantigen sources with Ervaxx, Precision Biologics and Broad Institute
- How to maximize immunogenicity to drive clinical development & success with Gritstone Oncology, Genocea and Treos Bio
- Reducing complex process and release times by navigating through complex manufacturing challenges with Achilles Therapeutics, Vaximm and ISA Therapeutics
Download the official brochure to see what sessions will help you to advance your cancer immunotherapy pipeline.
Join us online to gain the practical insights you need to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy.